放射性核素^(131)I在甲亢治疗中的安全性与有效性  

Efficacy and Safety of Radionuclide ^(131)I in the Treatment of Hyperthyroidism

作　　者：徐智军 于鹏 梁英魁[3] 王政清 王玉华 

机构地区：[1]河北省唐山市中医医院核医学科,河北唐山063000 [2]华北理工大学附属医院核医学科,河北唐山063000 [3]海军总医院核医学科,北京100048

出　　处：《现代生物医学进展》2017年第19期3762-3764,共3页Progress in Modern Biomedicine

摘　　要：目的:探讨放射性核素^(131)I应用于甲亢治疗的安全性与有效性。方法:选择2013年8月到2016年2月选择在我院诊治的甲亢患者240例,根据随机信封抽签原则分为观察组与对照组各120例,对照组口服丙硫氧嘧啶片治疗,观察组在对照组治疗的基础上给予放射性核素^(131)I治疗,治疗观察3个月,记录治疗的安全性与有效性。结果:治疗后,观察组总有效率为96.7%,明显高于对照组的86.7%(P<0.05)。观察组治疗后血清甲状腺激素水平明显低于治疗前及对照组(P<0.05)。观察组治疗期间的甲减、粒细胞减少、肝脏损害、贫血等不良反应发生率为11.7%,对照组为10.8%,两组不良反应的发生率对比差异无统计学意义(P>0.05)。结论:放射性核素^(131)I可使甲亢患者的甲状腺激素的分泌和合成显著减少,安全性及有效性均较高。Objective：To explore the efficacy and safety of radionuclide ^131I in the treatment of hyperthyroidism.Methods：From August 2013 to February 2016,240 cases of patients with hyperthyroidism in our hospital were selected and randomly divided into the observation group and control group with 120 cases of patients in each group.The control group was treated with propylthiouracil tablets,while the observation group was given mdionuclide ^131I treatment based on the treatment of control group,all the patients were treated for 3 months,and the safety and efficacy were recorded.Results：The total effective rate of observation group and control group were 96.7% and 86.7% respectively,the total effective rate of observation group was significantly higher than that of the control group （P〈0.05）.After treatment,the serum levels of FT3 and FT4 in the observation group were significantly lower than those before treatment and those in the control group （P〈0.05）.The adverse reaction of observation group during the treatment included hypothyroidism,neutropenia,anemia,liver damage and the incidence rate was 11.7%,which was 10.8% in the control group,no significant difference was observed between two groups（P〉0.05）.Conclusion：Radionuclide ^131I was safe and effective in the treatment of hyperthyroidism,which could reduce the secretion and synthesis of thyroid hormone.

关 键 词：放射性核素^131I 甲亢 不良反应 甲状腺激素 

分 类 号：R582.1[医药卫生—内分泌]